Baird Maintains a 'Neutral' on MannKind (MNKD), Sees $1 Upside in Near-Term
More News related to MNKD
- SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
- SemBioSys receives US$2.5 million in option agreement with MannKind for plant-produced insulin
- MannKind to Present at the 27th Annual J.P. Morgan Healthcare Conference
- Notable Analyst Rating Changes 12/18: BLK, STLD, LSCC Upgraded; KSS, WFR, BUCY, LVS Downgraded
- Oppenheimer Starts MannKind (MNKD) at Perform
More News related to Analyst Comments
- Buckingham Research Maintains a 'Neutral' Rating on Wal-Mart (WMT), See Upside/Downside Fairly Balanced
- Wedbush Morgan Maintains a 'Hold' on Majesco Holdings (COOL), Impressed With Progress But Investors Remain Skeptical
- Wedbush Morgan Maintains a 'Hold' on Family Dollar Stores (FDO), Raises Price Target and Estimates
- Wedbush Morgan Maintains a 'Buy' on ON Semiconductor (ONNN), Raises Price Target
- Analyst Round-Up: Intuitive Surgical (ISRG) - 3 Downgrades, 2 Price Target Cuts
Baird maintains a 'Neutral' on MannKind Corporation (Nasdaq: MNKD). Price target $4.
Baird analyst says, "We are incrementally positive on Neutral-rated MNKD and believe the stock could gain ~$1 over the near term. Assuming detailed data and secondary endpoints do not disappoint two weeks from now, we believe positive pivotal trial data for Afresa (Technosphere Insulin) may be seen as a de-risking event. The next catalysts are additional data during the week of 12/15/08, NDA filing around late-January, and possible commercial partnership later in 2009...No changes to model/EPS for now. We assume 67% probability of regulatory approval and commercial success and would typically move to 85% upon NDA filing. Sensitivity analysis suggests this would correlate to $1/share."
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.
Related Categories
Analyst CommentsStocks Mentioned
+0.16Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
